Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy and High-Dose Radiation in Stage III NSCLC
NCT00033553Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2002
- Primary completion
- Sep 2006
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Paclitaxel Micelles for Injection and gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Response Rate at 18 months. Started Mar 2002; status: completed.
02
Drugs
Paclitaxel Micelles for Injectiongemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00033553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033553.